- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00036114
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
November 7, 2013 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
Study Overview
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Tuscaloosa, Alabama, United States
- Local Institution
-
-
Arizona
-
Scottsdale, Arizona, United States
- Local Institution
-
-
California
-
Cerritos, California, United States
- Local Institution
-
Granada Hills, California, United States
- Local Institution
-
Los Angeles, California, United States
- Local Institution
-
San Diego, California, United States
- Local Institution
-
Torrance, California, United States
- Local Institution
-
-
Colorado
-
Denver, Colorado, United States
- Local Institution
-
-
Connecticut
-
Hamden, Connecticut, United States
- Local Institution
-
-
Florida
-
Miami, Florida, United States
- Local Institution
-
North Miami Beach, Florida, United States
- Local Institution
-
West Palm Beach, Florida, United States
- Local Institution
-
-
Georgia
-
Atlanta, Georgia, United States
- Local Institution
-
Augusta, Georgia, United States
- Local Institution
-
Macon, Georgia, United States
- Local Institution
-
-
Hawaii
-
Honolulu, Hawaii, United States
- Local Institution
-
-
Illinois
-
North Chicago, Illinois, United States
- Local Institution
-
Springfield, Illinois, United States
- Local Institution
-
-
Louisiana
-
New Orleans, Louisiana, United States
- Local Institution
-
Shreveport, Louisiana, United States
- Local Institution
-
-
Maryland
-
Baltimore, Maryland, United States
- Local Institution
-
-
Massachusetts
-
Newton Center, Massachusetts, United States
- Local Institution
-
Springfield, Massachusetts, United States
- Local Institution
-
Wellesley Hills, Massachusetts, United States
- Local Institution
-
-
New Jersey
-
Lyons, New Jersey, United States
- Local Institution
-
-
New York
-
Albany, New York, United States
- Local Institution
-
Lawrence, New York, United States
- Local Institution
-
Montrose, New York, United States
- Local Institution
-
Northport, New York, United States
- Local Institution
-
White Plains, New York, United States
- Local Institution
-
-
North Carolina
-
Raleigh, North Carolina, United States
- Local Institution
-
-
Ohio
-
Beachwood, Ohio, United States
- Local Institution
-
-
Oregon
-
Portland, Oregon, United States
- Local Institution
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States
- Local Institution
-
-
Texas
-
Austin, Texas, United States
- Local Institution
-
Dallas, Texas, United States
- Local Institution
-
San Antonio, Texas, United States
- Local Institution
-
Wichita Falls, Texas, United States
- Local Institution
-
-
Vermont
-
Bennington, Vermont, United States
- Local Institution
-
-
Virginia
-
Charlottesville, Virginia, United States
- Local Institution
-
-
Washington
-
Seattle, Washington, United States
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Institutionalized patients with Alzheimer's
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2000
Primary Completion (Actual)
August 1, 2003
Study Completion (Actual)
August 1, 2003
Study Registration Dates
First Submitted
May 7, 2002
First Submitted That Met QC Criteria
May 8, 2002
First Posted (Estimate)
May 9, 2002
Study Record Updates
Last Update Posted (Estimate)
November 11, 2013
Last Update Submitted That Met QC Criteria
November 7, 2013
Last Verified
April 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
Other Study ID Numbers
- CN138-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on aripiprazole
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityCompleted
-
Otsuka Beijing Research InstituteCompleted
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
University of California, Los AngelesAlkermes, Inc.TerminatedSchizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive TypeUnited States
-
Otsuka Pharmaceutical Co., Ltd.CompletedMajor Depressive DisorderJapan
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Otsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaJapan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Alkermes, Inc.CompletedSchizophreniaUnited States
-
Alkermes, Inc.CompletedSchizophreniaUnited States